NGM Biopharmaceuticals Inc (DELISTED) (NGM:DL)
1.54
0.00 (0.00%)
USD |
NASDAQ |
Apr 05, 16:00
NGM Biopharmaceuticals Cash from Financing (Quarterly): 0.111M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.111M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 1.385M |
| March 31, 2023 | 0.279M |
| December 31, 2022 | 0.723M |
| September 30, 2022 | 33.22M |
| June 30, 2022 | 19.62M |
| March 31, 2022 | 0.668M |
| December 31, 2021 | 2.378M |
| September 30, 2021 | 3.478M |
| June 30, 2021 | 3.324M |
| March 31, 2021 | 140.48M |
| Date | Value |
|---|---|
| December 31, 2020 | 27.61M |
| September 30, 2020 | 0.908M |
| June 30, 2020 | 3.427M |
| March 31, 2020 | 3.591M |
| December 31, 2019 | 3.573M |
| September 30, 2019 | 0.643M |
| June 30, 2019 | 176.54M |
| March 31, 2019 | -0.003M |
| December 31, 2018 | -1.058M |
| September 30, 2018 | 1.207M |
| June 30, 2018 | 0.163M |
| March 31, 2018 | -0.114M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
Sep 2023
176.54M
Maximum
Jun 2019
22.21M
Average
3.324M
Median
Jun 2021
Cash from Financing (Quarterly) Benchmarks
| Catalent Inc | 0.00 |
| AIM ImmunoTech Inc | 2.829M |
| Perspective Therapeutics Inc | 166.33M |
| Protalix BioTherapeutics Inc | 0.00 |
| Armata Pharmaceuticals Inc | 34.93M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -22.96M |
| Cash from Investing (Quarterly) | 27.19M |
| Free Cash Flow | -133.45M |
| Free Cash Flow Per Share (Quarterly) | -0.2796 |
| Free Cash Flow to Equity (Quarterly) | -23.15M |
| Free Cash Flow Yield | -105.0% |